HEALTHPEAK PROPERTIES, INC. (DOC) Stock News

Doximity (DOCS) closed at $30.71, down 2.51%, underperforming the S&P 500. The medical social networking company is scheduled to report earnings on November 5, 2026, with projected EPS of $0.34 (down 24.44% YoY) and revenue of $170.66 million (up 1.27% YoY). The stock holds a Zacks Rank #3 (Hold) with a Forward P/E of 23.61, trading at a discount to its industry average.

Teladoc (TDOC) closed at $6.00, up 1.35% in the latest session, outperforming the S&P 500. However, the stock has declined 8.92% over the past month. The company is expected to report negative EPS of -$0.23 and revenue of $585.55 million, down 6.53% year-over-year. Teladoc holds a Zacks Rank of #3 (Hold), with consensus EPS estimates unchanged over the last 30 days.

Rosen Law Firm reminds investors who purchased Doximity, Inc. (DOCS) shares between August 8, 2024 and May 13, 2026 of the November 16, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges Doximity misrepresented the impact of its news feed feature on revenue growth while losing market share to competitors with better pricing and user engagement models.

Rosen Law Firm is urging investors who purchased Doximity common stock between August 8, 2024 and May 13, 2026 to join a securities class action lawsuit before the November 16, 2026 lead plaintiff deadline. The lawsuit alleges that Doximity overstated the revenue impact of its Newsfeed feature, lost market share to competitors, and relied on less effective engagement tactics, causing investor damages when the truth emerged.

Teladoc (TDOC) declined 3.64% in the latest trading session, significantly underperforming the broader market. The stock has depreciated 7.83% over the past month, underperforming the Medical sector. Upcoming earnings are projected to show a loss of $0.23 per share with revenue declining 6.53% year-over-year. The company holds a Zacks Rank of #3 (Hold) with unchanged consensus EPS estimates over the last 30 days.

Law Offices of Howard G. Smith has filed securities fraud class action lawsuits against four publicly-traded companies: Better Home & Finance (BETR), Doximity (DOCS), Baidu (BIDU), and UWM Holdings (UWMC). The lawsuits allege that defendants made materially false statements and failed to disclose material adverse facts about their business operations. Investors have until specified deadlines in October and November 2026 to file lead plaintiff motions.

Doximity (DOCS) closed at $28.58, up 2.33%, outperforming the S&P 500's 0.66% gain. The stock has gained 6% over the past month despite the Medical sector declining 3.74%. Upcoming earnings are expected to show an EPS of $0.34 (down 24.44% YoY) with revenue of $170.66 million (up 1.27% YoY). The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 20.93, trading at a discount to its industry average of 31.16.

A class action securities fraud lawsuit has been filed against Doximity, Inc. for allegedly making materially false statements about its business operations. The company failed to disclose that it overstated its Newsfeed's revenue impact, was losing market share to competitors, and relied on less effective advertising tactics. Doximity's stock declined significantly following three disappointing earnings announcements between November 2025 and May 2026, with the company missing guidance and projecting slower growth. The deadline to file a lead plaintiff motion is November 16, 2026.

Rosen Law Firm is reminding investors who purchased Doximity common stock between August 8, 2024 and May 13, 2026 to join a securities class action lawsuit before the November 16, 2026 lead plaintiff deadline. The lawsuit alleges that Doximity overstated the revenue impact of its Newsfeed feature and lost market share to competitors while relying on less effective advertising methods.

Rosen Law Firm reminds investors who purchased Doximity Inc. (DOCS) shares between August 8, 2024 and May 13, 2026 of the November 16, 2026 deadline to file a securities class action lawsuit. The lawsuit alleges that Doximity misrepresented the impact of its news feed on revenue growth while losing market share to competitors with better pricing and user engagement models.

Rosen Law Firm has filed securities class action lawsuits against Doximity, Inc., Qfin Holdings, Inc., and Beta Bionics, Inc., alleging investor damages. The primary case detailed involves Doximity, which allegedly overstated its Newsfeed's revenue impact and lost market share to competitors. Investors have until November 16, 2026 to serve as lead plaintiff.

Teladoc stock declined 2.38% to $5.75, underperforming the broader market. The telehealth provider has dropped 7.1% over the past month, significantly worse than the Medical sector's 0.67% loss. Upcoming earnings are projected at -$0.23 per share with quarterly revenue expected at $585.55 million, down 6.53% year-over-year. The stock holds a Zacks Rank of #3 (Hold) with recent analyst estimate revisions showing a 1.62% decrease.

Rosen Law Firm is reminding investors in Doximity, DNOW Inc., and XTI Aerospace of upcoming deadlines to join securities class action lawsuits. The firm is seeking lead plaintiffs for cases alleging various corporate misconduct including revenue overstatement and market share losses.

The Law Offices of Frank R. Cruz has announced class action lawsuits against four publicly-traded companies for allegedly making materially false and misleading statements to investors. Baidu faces allegations of overstating its AI business capabilities, Doximity of misrepresenting its Newsfeed's revenue impact, Better Home & Finance of concealing conversion funnel slowdowns, and Honeywell Aerospace of failing to disclose supplier constraints and cybersecurity investigation issues. Lead plaintiff deadlines range from November 13-23, 2026.

A class action lawsuit has been filed against Doximity, Inc. (NYSE: DOCS) for alleged violations of securities laws. The complaint alleges the company made false and misleading statements regarding its Newsfeed product's impact on revenue growth, overstated market position amid competitive pricing pressures, and misrepresented its advertising delivery methods. The class period spans August 8, 2024 to May 13, 2026, with a deadline of November 16, 2026 for investors to participate.

Rosen Law Firm has filed class action lawsuits against Doximity, Inc., Honeywell Aerospace Inc., and UWM Holdings Corporation on behalf of investors who purchased securities during specified periods. The lawsuit against Doximity alleges the company overstated Newsfeed revenue impact and lost market share to competitors. Investors are encouraged to secure counsel before the November 16, 2026 deadline to serve as lead plaintiff.

Grabar Law Office announced investigations into potential breaches of fiduciary duties by officers and directors at Doximity, GoDaddy, Planet Fitness, and PROCEPT BioRobotics. The investigations follow federal securities class action filings alleging misleading statements regarding business metrics, pricing strategies, and financial guidance. Long-term shareholders meeting specific holding periods are eligible to seek corporate reforms and potential compensation at no cost.

Teladoc (TDOC) fell 3.46% in trading, outpacing the broader market decline. The telehealth services provider faces headwinds with projected EPS of -$0.23 (down 9.52% YoY) and revenue expected at $585.55 million (down 6.53% YoY). The stock holds a Zacks Rank #3 (Hold) rating, with consensus EPS estimates declining 1.78% over the last 30 days.

Wolf Haldenstein has filed class action lawsuits against Doximity, Papa John's International, and Hims & Hers Health on behalf of shareholders who suffered losses. The lawsuits allege that these companies made false or misleading statements regarding their financial performance and business prospects. Doximity's stock declined significantly following multiple guidance misses and revenue warnings between November 2025 and May 2026.

Pomerantz Law Firm has filed a class action lawsuit against Doximity, Inc. for alleged securities fraud following three significant stock price declines in late 2025 and mid-2026. The company faced investor losses after issuing cautious guidance despite strong quarterly results, subsequently lowering revenue guidance and missing projections. The firm is also investigating claims against FuelCell Energy and Jackson Financial.

Doximity (DOCS) closed at $26.84, up 2.8%, outperforming the S&P 500's 1.49% gain. The medical social networking company is expected to report Q earnings of $0.34 per share (down 24.44% YoY) with revenue of $170.66 million (up 1.27% YoY). For the full fiscal year, earnings are projected at $1.33 per share (down 12.5%) and revenue at $675.74 million (up 4.79%). Trading at a Forward P/E of 19.57, below its industry average of 28.23, Doximity holds a Zacks Rank of #3 (Hold).

Rosen Law Firm has filed class action lawsuits against Doximity, Inc., PROCEPT BioRobotics Corporation, and DNOW Inc. on behalf of investors who suffered losses. The Doximity lawsuit alleges the company overstated its Newsfeed's revenue impact and lost market share to competitors. Investors with losses exceeding $100,000 are encouraged to seek counsel before upcoming deadlines.

Teladoc (TDOC) declined 2.33% to $6.28, underperforming the broader market which gained 1.14%. The telehealth services provider faces headwinds with projected EPS of -$0.23 (down 9.52% YoY) and revenue expected at $585.55 million (down 6.53% YoY). The stock holds a Zacks Rank #3 (Hold) rating with EPS estimates revised 1.28% lower over the past 30 days.

Doximity stock fell 2.2% on September 15, 2026, outpacing the broader market decline. The medical social networking company is expected to report a 24.44% EPS decline for the upcoming quarter, though revenue is projected to grow 1.27% year-over-year. The stock holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 19.78, trading at a discount to its industry average.

DocuSign reported Q3 2026 earnings of $1.16 per share, beating consensus estimates of $1.08, with revenues of $875.75 million slightly exceeding expectations. However, the stock has underperformed the S&P 500 by 16.4% year-to-date. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions. Cognyte Software, in the same Internet-Software industry, is expected to report results on September 9 with projected earnings of $0.09 per share.

Teladoc Health (TDOC) is positioned for growth through chronic care expansion, international presence, and its upcoming Teladoc One platform, with the stock trading at a valuation discount. However, the company faces headwinds from declining BetterHelp revenues, intense virtual care competition, and persistent unprofitability with a $16.5 billion accumulated deficit.

Wall Street analysts forecast DocuSign will report Q2 earnings of $1.08 per share (up 17.4% YoY) with revenues of $867.65 million (up 8.4% YoY). EPS estimates were revised down 1.1% over the past month. Key metrics show subscription revenue at $848.94 million (+8.2% YoY), total customers at 1.90 million, and enterprise/commercial customers at 289.32 thousand. DocuSign shares gained 12.3% over the past month and hold a Zacks Rank #2 (Buy) rating.

A comparison of DocuSign (DOCU) and Autodesk (ADSK) as potential value stock investments in the Internet-Software sector. DocuSign emerges as the better value option with a Zacks Rank #2 (Buy) versus Autodesk's Rank #3 (Hold), a lower forward P/E ratio of 13.06 compared to 20.17, and a Value grade of B versus D. DocuSign's stronger earnings estimate revisions and more attractive valuation metrics make it the preferred choice for value investors.

Pomerantz LLP is investigating potential securities fraud claims against Teladoc Health following the company's significant revenue guidance downgrade on July 29, 2026. Teladoc reduced its full-year 2026 revenue guidance from $2.48-$2.58 billion to $2.36-$2.45 billion, citing uncertainties in cash pay and business model transition. The announcement triggered a 38.32% stock price decline, falling $2.60 per share to $6.58.